Soft Tissue Sarcoma Market is Expected To Register a CAGR of 8.2% with Major Treatment as Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, and Radiation Therapy Forecasts to 2023

The Global Soft Tissue Sarcoma market is expected to register an approximate CAGR of 7.4% during the forecast period owing to the growing biotechnology and pharmaceutical sector and rising investments in the medical sector and life sciences. A majority of the Soft Tissue Sarcomas are utilized by the pharmaceutical and biotechnology sectors for various quality control processes, R&D practices, and others. In 2017, according to the Biotechnology and Biological Sciences Research Council, the U.K pharmaceutical market is expected to grow with an average annual growth rate of 4 to 7% by 2021. Such trends in the growth of the pharmaceutical sector provide favorable backgrounds for the market, by increasing the demand for Soft Tissue Sarcomas.

Moreover, increasing investments in life sciences boost the market growth. Recently in 2018, Innovate U.K. funded over 12 million pounds to enable merging technologies in health and life sciences sectors. Life sciences involve a scientific study of microorganisms, plants, and animals including human beings through experimentations and activities such as tissue culturing, microbial studies, and others. These activities are tedious and easily prone to contaminations. The reason for the same can range from the use of contaminated media to improper handling. An easy way to avoid the contamination is the use of biosafety cabinets that provide a sterile platform for such experiments. Therefore, the demand for Soft Tissue Sarcomas is estimated to increase with the rising investments followed by the growth of life sciences.

Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/5304

However, the high cost of Soft Tissue Sarcomas and presence of alternative containment cabinets in the market are estimated to restrain the market growth during the forecast period. The cost of Soft Tissue Sarcomas by market players such as Thermo Fisher Scientific is high. It is estimated to range from ~ USD 9,500 to USD 12,000. In the presence of such high price, a reluctance is seen in the market in terms of product acceptance. This is estimated to restrain the market growth during the forecast period.

Top Players in Soft Tissue Sarcoma Market:

Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Market Segmentation of Soft Tissue Sarcoma Market:

The soft tissue sarcoma is segmented on the basis of treatment, disease type, distribution channel, and end-users.

On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcatergorized into internal radiation therapy and external radiation therapy.

On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma
On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.
On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Regional Analysis of Soft Tissue Sarcoma Market:

The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.

Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.

The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304

Some of Major Table of Content for Soft Tissue Sarcoma Market:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
4.5 Macroeconomic Indicators

TOC Continued….!

Get Discount @ https://www.marketresearchfuture.com/check-discount/5304

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.